Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK investigational adjuvanted HPV vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GSK's investigational adjuvanted HPV vaccine is a 9-valent recombinant biologic vaccine candidate developed to prevent infections and associated clinical diseases caused by human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, and 58. The vaccine is formulated with GSK's proprietary AS04 adjuvant system, which combines aluminum hydroxide with 3-O-desacyl-4'-monophosphoryl lipid A (MPL), a Toll-like receptor 4 (TLR4) agonist. This adjuvant system is designed to enhance the magnitude and duration of the immune response compared to non-adjuvanted formulations. The vaccine is currently in Phase 1/2 clinical development (NCT05496231), where its safety, reactogenicity, and immunogenicity are being evaluated in healthy young women in comparison to the licensed 9-valent HPV vaccine (Gardasil 9).
- Other names
- GSK 9-valent HPV vaccineGSK9-valent HPV vaccineGSK-9-valent HPV vaccineGSK 9vHPV vaccineGSK9vHPV vaccineGSK-9vHPV vaccine
02
Targets
TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on GSK investigational adjuvanted HPV vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK investigational adjuvanted HPV vaccine.